<DOC>
	<DOCNO>NCT01809223</DOCNO>
	<brief_summary>This study design evaluate effect conbercept therapy visual acuity anatomic outcome compare sham injection durability response observe subject choroid neovascularization secondary pathological myopia .</brief_summary>
	<brief_title>A Randomized , Double-blind , Multicenter , Sham-controlled , Safety Efficacy Study Conbercept Patients With mCNV</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Myopia</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Myopia , Degenerative</mesh_term>
	<criteria>1 . Patients give fully inform consent willing able comply study procedure . 2 . In study eye : Myopia equal great 6.00D , axial length ≥26.5mm . Diagnosis active subfoveal , juxafoveal , extrafoveal CNV secondary high myopia . Visual impairment due CNV secondary high myopia . BCVA score ≥24 ≤73 ETDRS letter ( approximately 20/40~ 20/320 Snellen equivalent ) . Ocular medium sufficient quality obtain fundus OCT image . 3 . The BCVA score fellow eye ≥ 19 ETDRS letter ( approximately 20/400 Snellen equivalent ) 1 . Current vitreous hemorrhage either eye . 2 . Intraocular treatment corticosteroid within last 3 month periocular treatment corticosteroid within last month study eye . 3 . Active infectious ocular inflammation either eye . 4 . Fibrosis atrophy involve center foveal study eye . 5 . Any concurrent intraocular condition study eye , opinion investigator , could either require medical surgical intervention study period prevent treat visual loss might result condition . 6 . The lesion size ≥30 mm2 study eye . 7 . Any ocular disorder study eye , opinion investigator , may confound interpretation study result . 8 . Uncontrolled glaucoma cup/disk ratio &gt; 0.8 study eye . 9 . Aphakia ( exclude artificial lens ) study eye . 10 . Serious amblyopia amaurosis fellow eye .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>